The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Estimated Market Size Of The Closed Viral Vector Manufacturing Platforms Market In 2026, And How Will Its Value Evolve By 2030?
The closed viral vector manufacturing platforms market has seen substantial growth over the past few years. It is anticipated to expand from $1.96 billion in 2025 to $2.22 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 13.4%. This historical growth can be attributed to factors such as an increase in gene therapy clinical trials, broader use of viral vectors in vaccine development, the expansion of cell and gene therapy research programs, a rising regulatory focus on sterile manufacturing, and the early adoption of closed processing technologies.
The closed viral vector manufacturing platforms market size is projected to experience significant expansion in the coming years. It is expected to reach $3.63 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 13.1%. This growth during the forecast period can be attributed to the increasing commercialization of gene therapies, a rising demand for large-scale viral vector supply, growing investments in advanced biomanufacturing infrastructure, the expansion of contract manufacturing capacity, and an increasing focus on process standardization and automation. Major trends anticipated in this period include the increasing adoption of fully closed and automated production systems, a rising demand for scalable viral vector manufacturing platforms, the growing integration of single-use and modular components, the expansion of end-to-end closed processing workflows, and an enhanced focus on regulatory compliance and contamination control.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28981&type=smp
Which Major Drivers Are Influencing The Expansion Of The Closed Viral Vector Manufacturing Platforms Market?
The rising volume of clinical trials is anticipated to propel the expansion of the closed viral vector manufacturing platforms market in the foreseeable future. Clinical trials are meticulously designed studies conducted in humans to evaluate the safety, efficacy, and appropriate application of new medical treatments or interventions. The increasing demand for clinical trials is driven by the growing requirement for innovative therapies, as the rising prevalence of chronic and complex diseases necessitates the development and testing of new drugs and treatments to address unmet medical needs. Closed viral vector manufacturing platforms facilitate clinical trials by ensuring the consistent, sterile production of viral vectors, which in turn guarantees the safety and reliability of the therapies being investigated. For instance, in December 2024, figures from the Association of the British Pharmaceutical Industry (ABPI), a UK-based trade association, indicated that the overall number of industry-sponsored clinical trials launched in the UK increased from 411 in 2022 to 426 in 2023. Thus, the escalating number of clinical trials is a key factor driving the growth of the closed viral vector manufacturing platforms market.
Which Segment Classifications Are Used In The Closed Viral Vector Manufacturing Platforms Market Segment Analysis?
The closed viral vector manufacturing platforms market covered in this report is segmented –
1) By Product Type: Plasmid Deoxyribonucleic Acid (DNA), Lentiviral Vectors, Adenoviral Vectors, Adeno-Associated Viral Vectors, Retroviral Vectors, Other Product Types
2) By Workflow: Upstream Processing, Downstream Processing, Fill-Finish
3) By Application: Gene Therapy, Vaccines, Cell Therapy, Other Applications
4) By End User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Contract Manufacturing Organizations, Other End Users
Subsegments:
1) By Plasmid Deoxyribonucleic Acid (DNA): Supercoiled DNA, Linearized DNA, Minicircle DNA
2) By Lentiviral Vectors: Integrating Lentiviral Vectors, Non-Integrating Lentiviral Vectors
3) By Adenoviral Vectors: Replication-Deficient Adenoviral Vectors, Replication-Competent Adenoviral Vectors
4) By Adeno-Associated Viral Vectors (AAV): Single-Stranded AAV (ssAAV), Self-Complementary AAV (scAAV)
5) By Retroviral Vectors: Gamma-Retroviral Vectors, Alpha-Retroviral Vectors
6) By Other Product Types: Herpes Simplex Virus (HSV) Vectors, Vaccinia Virus Vectors, Baculovirus Vectors
What Trends Are Transforming The Closed Viral Vector Manufacturing Platforms Market?
Key companies in the closed viral vector manufacturing platforms market are prioritizing the creation of advanced solutions, including nitro controllers, to avert nitrogen-induced stress or toxicity in cell cultures. These nitro controllers serve as devices or systems for monitoring and regulating nitrogen levels or reactive nitrogen species during bioprocesses, thereby securing optimal environments for cell proliferation and product synthesis. For example, in May 2025, Univercells Technologies, a biotechnology firm headquartered in Belgium, unveiled its scale-X nitro controller. This system is a compact and cost-effective solution specifically designed for the large-scale manufacturing of viral vectors and vaccines. It offers compatibility with 200 m² and 600 m² scale-X nitro bioreactors and accommodates both adherent and suspension cell cultures. The system facilitates the efficient generation of AAV, lentiviral vectors, exosomes, and oncolytic viruses. Furthermore, it permits rapid scale-up, aiding the progression from research and development to commercial manufacturing within an eight-month timeframe.
Which Firms Are Contributing To The Closed Viral Vector Manufacturing Platforms Market Ecosystem?
Major companies operating in the closed viral vector manufacturing platforms market are Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group AG, WuXi AppTec, Samsung Biologics Co. Ltd., FUJIFILM Biotechnologies, Oxford Biomedica Plc, Hillgene, Takara Bio Inc., SkyPharma Production SAS, GeneScript ProBio, Obio Technology Corp. Ltd., VectorBuilder, Charles River Laboratories Pvt. Ltd., Creative Biogene, Esco Aster Pte. Ltd., Karma Biotechnologies, Cell and Gene Therapy Catapult, CoJourney, Applied Biological Laboratories Inc., CEVEC Pharmaceuticals, Genesail Biotech Co. Ltd.
Get The Full Closed Viral Vector Manufacturing Platforms Market Report:
Where Is The Closed Viral Vector Manufacturing Platforms Market Most Concentrated Geographically?
North America was the largest region in the Closed Viral Vector Manufacturing Platforms market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the closed viral vector manufacturing platforms market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Closed Viral Vector Manufacturing Platforms Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Closed Viral Vector Manufacturing Platforms Market 2026, By The Business Research Company
Viral Vector Manufacturing Market Report 2026
https://www.thebusinessresearchcompany.com/report/viral-vector-manufacturing-global-market-report
Viral And Non Viral Vector Manufacturing Market Report 2026
Oral Expectorant Market Report 2026
https://www.thebusinessresearchcompany.com/report/oral-expectorant-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model